Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 6/2018

01-06-2018 | Review – Cancer Research

Role of natural killer cells in lung cancer

Authors: Ozge Nur Aktaş, Ayşe Bilge Öztürk, Baran Erman, Suat Erus, Serhan Tanju, Şükrü Dilege

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2018

Login to get access

Abstract

Purpose

One of the key immune cells involved in the pathogenesis of lung cancer is natural killer (NK) cells and these cells are novel targets for therapeutic applications in lung cancer. The purpose of this review is to summarize the current literature on lung cancer pathogenesis with a focus on the interaction between NK cells and smoking, how these factors are related to the pathogenesis of lung cancer and how NK cell-based immunotherapy effect lung cancer survival.

Methods

The relevant literature from PubMed and Medline databases is reviewed in this article.

Results

The cytolytic potential of NK cells are reduced in lung cancer and increasing evidence suggests that improving NK cell functioning may induce tumor regression. Recent clinical trials on NK cell-based novel therapies such as cytokines including interleukin (IL)-15, IL-12 and IL-2, NK-92 cell lines and allogenic NK cell immunotherapy showed promising results with less adverse effects on the lung cancer survival.

Conclusions

The NK cell targeting strategy has not yet been approved for lung cancer treatment. More clinical studies focusing on the role of NK cells in lung cancer pathogenesis are warranted to develop novel NK cell-based therapeutic approaches for the treatment of lung cancer.
Literature
Al Omar SY, Marshall E, Middleton D, Christmas SE (2011) Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology 133(1):94–104CrossRefPubMedPubMedCentral
Andreoli C, Bassi A, Gregg EO, Nunziata A, Puntoni R, Corsini E (2015) Effects of cigarette smoking on circulating leukocytes and plasma cytokines in monozygotic twins. Clin Chem Lab Med 53(1):57–64CrossRefPubMed
Anton-Culver H, Chang J, Bray F, Znaor A, Stevens L, Eser S et al (2016) Cancer burden in four countries of the Middle East Cancer Consortium (Cyprus; Jordan; Israel; Izmir Turkey) with comparison to the United States surveillance; epidemiology and end results program. Cancer Epidemiol 44:195–202CrossRefPubMed
Bauer S et al (1999) Activation of natural killer cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–730CrossRefPubMed
Boutet P et al (2009) Cutting edge: the metalloproteinase ADAM17/TNF-α-converting enzyme regulates proteolytic shedding of the MHC class I‑related chain B protein. J Immunol 182:49–53CrossRefPubMed
Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G (2008) Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(−) cells and display an impaired capability to kill tumor cells. Cancer 112(4):863–875CrossRefPubMed
Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100(7):4120–4125CrossRefPubMedPubMedCentral
Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640CrossRefPubMed
Cui F, Ji J, Lv H, Qu D, Yu C, Yang Y, Xu Y (2013) Immune responsiveness in a mouse model of combined adoptive immunotherapy with NK and dendritic cells. J Cancer Res Ther 9(Suppl):S162–S168PubMed
De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, Catalano G (2000) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117:365–373CrossRefPubMed
Deniz G, van de Veen W, Akdis M (2013) Natural killer cells in patients with allergic diseases. J Allergy Clin Immunol 132(3):527–535CrossRefPubMed
Ding X, Cao H, Chen X, Jin H, Liu Z, Wang G, Cai L, Li D, Niu C, Tian H, Yang L, Zhao Y, Li W, Cui J (2015) Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. J Transl Med 13:158CrossRefPubMedPubMedCentral
Esendagli G, Bruderek K, Goldmann T, Busche A, Branscheid D, Vollmer E, Brandau S (2008) Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 59(1):32–40CrossRefPubMed
Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M et al (2016) Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. Oncoimmunology 6(1):e1163456CrossRefPubMedPubMedCentral
Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A, Münz C (2004) The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 172(3):1455–1462CrossRefPubMed
Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T, Yamazaki H, Inoue H et al (2000) Clinical implications of interleukin-10 induced by non-small-cell lung cancer. Ann Oncol 11:815–819CrossRefPubMed
Hiraki A, Kiura K, Yamane H, Nogami N, Tabata M, Takigawa N, Ueoka H, Tanimoto M, Harada M (2002) Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer 35(3):329–333CrossRefPubMed
Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M, Reynolds PN, Jersmann H, Hodge S (2014) Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. Clin Exp Immunol 178(1):79–85CrossRefPubMedPubMedCentral
Huang AL, Liu SG, Qi WJ, Zhao YF, Li YM, Lei B, Sheng WJ, Shen H (2014) TGF-β1 protein expression in non-small cell lung cancers is correlated with prognosis. Asian Pac J Cancer Prev 15(19):8143–8147CrossRefPubMed
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2004) Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 83:1–1438PubMedCentral
Jonges LE, Albertsson P, van Vlierberghe RL, Ensink NG, Johansson BR, van de Velde CJ et al (2001) The phenotypic heterogeneity of human natural killer cells: presence of at least 48 different subsets in the peripheral blood. Scand J Immunol 53:103–110CrossRefPubMed
Kim S, Iizuka K, Aguila HL et al (2000) In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 97(6):2731–2736CrossRefPubMedPubMedCentral
Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G et al (2004) Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res 10:3699–3707CrossRefPubMed
Li Yang L, Wang, Zhang Y (2016) Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol 5(1):1–20PubMed
Lin M, Liang SZ, Wang XH et al (2017) Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunol Res 65(4):880–887CrossRefPubMed
Loza MJ, Perussia B (2004) The IL‑12 signature: NK cell terminal CD56+ high stage and effector functions. J Immunol 172:88–96CrossRefPubMed
Lu LM, Zavitz CC, Chen B, Kianpour S, Wan Y, Stämpfli MR (2007) Cigarette smoke impairs NK cell-dependent tumor immune surveillance. J Immunol 178(2):936–943CrossRefPubMed
Luna JI, Grossenbacher SK, Murphy WJ, Canter RJ (2017) Targeting cancer stem cells with natural killer cell immunotherapy. Expert Opin Biol Ther 17(3):313–324CrossRefPubMed
Luppi P, Lain KY, Jeyabalan A, DeLoia JA (2007) The effects of cigarette smoking on circulating maternal leukocytes during pregnancy. Clin Immunol 122(2):214–219CrossRefPubMed
Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, Wang L, Shifrin N, Raulet DH (2014) Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 122:91–128CrossRefPubMedPubMedCentral
Mian MF, Lauzon NM, Stampfli MR, Mossman KL, Ashkar AA (2008) Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J Leukoc Biol 83:74–784CrossRef
Mian MF, Pek EA, Mossman KL, St€ampfli MR, Ashkar AA (2009a) Exposure to cigarette smoke suppresses IL-15 generation and its regulatory NK cell functions in poly I: C-augmented human PBMCs. Mol Immunol 46:3108e16
Mian MF, Pek EA, Mossman KL, Stampfli MR, Ashkar AA (2009b) Exposure to cigarette smoke suppresses IL-15 generation and its regulatory NK cell functions in poly I:C-augmented human PBMCs. Mol Immunol 46:3108–3116CrossRefPubMed
Mian MF, Steampfli MR, Mossman KL, Ashkar AA (2009c) Cigarette smoke attenuation of poly I: C-induced innate antiviral responses in human PBMC is mainly due to inhibition of IFNbeta production. Mol Immunol 46:825e9
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE et al (2015) Molecularly targeted therapies in non small cell lung cancer annual update 2014. J Thorac Oncol 10(101):S1–S63CrossRefPubMedPubMedCentral
Moszczyński P, Zabiński Z, Moszczyński P Jr, Rutowski J, Słowiński S, Tabarowski Z (2001) Immunological findings in cigarette smokers. Toxicol Lett 118(3):121–127CrossRefPubMed
Motz GT, Eppert BL, Wortham BW, Amos-Kroohs RM, Flury JL, Wesselkamper SC, Borchers MT (2010) Chronic cigarette smoke exposure primes NK cell activation in a mouse model of chronic obstructive pulmonary disease. J Immunol 184:4460–4469CrossRefPubMed
Ndhlovu LC, Lopez-Vergès S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, Lanier LL (2012) Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119(16):3734–3743CrossRefPubMedPubMedCentral
Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L (2001) Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31(4):1076–1086CrossRefPubMed
Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71(16):5412–5422CrossRefPubMed
Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J (2009) CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126:458–465CrossRefPubMedPubMedCentral
Romee R et al (2013) NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease‑17 (ADAM17). Blood 121:3599–3608CrossRefPubMedPubMedCentral
Schneider T, Kimpfler S, Warth A, Schnabel PA, Dienemann H, Schadendorf D, Hoffmann H, Umansky V (2011) Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 6(3):432–438CrossRefPubMed
Sopori ML, Gairola CC, DeLucia AJ, Bryant LR, Cherian S (1985) Immune responsiveness of monkeys exposed chronically to cigarette smoke. Clin Immunol Immunopathol 36(3):338CrossRefPubMed
Specht HM, Pelzel J, Hautmann H, Huber RM, Schossow B, Molls M, Multhoff G (2014) P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT)—clinical application of NK cells activated by heat shock protein 70 (Hsp70). J Immunother Cancer 2(Suppl 2):P41CrossRefPubMedCentral
Tonn T, Schwabe D, Klingemann HG et al (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15(12):1563–1570CrossRefPubMed
Villegas FR, Coca S, Villarrubia VG, Jime´nez R, Chillo´n MJ et al (2002) Prognostic significance of tumor infiltrating natural killer cells subset CD57 inpatients with squamous cell lung cancer. Lung Cancer 35:23–28CrossRefPubMed
Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44CrossRefPubMedPubMedCentral
Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, He J, Wu G, Liu X, Zhang Y (2015) Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 29(2):635–641CrossRefPubMed
Zhang G, Zhao H, Wu J, Li J, Xiang Y, Wang G, Wu L, Jiao S (2014) Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: retrospective clinical observation. Int Immunopharmacol 21(2):396–405CrossRefPubMed
Metadata
Title
Role of natural killer cells in lung cancer
Authors
Ozge Nur Aktaş
Ayşe Bilge Öztürk
Baran Erman
Suat Erus
Serhan Tanju
Şükrü Dilege
Publication date
01-06-2018
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 6/2018
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-018-2635-3

Other articles of this Issue 6/2018

Journal of Cancer Research and Clinical Oncology 6/2018 Go to the issue

Original Article – Cancer Research

CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer

Original Article – Cancer Research

Cartilage oligomeric matrix protein is a prognostic factor and biomarker of colon cancer and promotes cell proliferation by activating the Akt pathway

Original Article – Clinical Oncology

MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach

Original Article – Clinical Oncology

Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms

Original Article – Cancer Research

Predictors of recurrence and survival of pathological T1N0M0 invasive adenocarcinoma following lobectomy

Original Article – Cancer Research

High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits